Trademark: 90539253
Status Date
Monday, October 24, 2022
Filing Date
Monday, February 22, 2021
Published for Opposition
Tuesday, January 25, 2022
Abandoned Date
Monday, October 24, 2022
5 Pharmaceutical preparations for treating cancer that assist in evaluating and matching common Human Leukocyte Antigen (HLA) with antigen reactivity to potential cancer patients by using predetermined parameters to optimize efficacy and safety
42 Development of methodologies in the field of medicine to optimize a match between cell product and patient, matching common Human Leukocyte Antigen (HLA) with antigen reactivity to potential cancer patients in order to enhance the efficacy of Human Leukocyte Antigen (HLA) and specific antigen
Oct 24, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Oct 24, 2022
Abandonment - No Use Statement Filed
Mar 22, 2022
Noa E-Mailed - Sou Required From Applicant
Jan 25, 2022
Official Gazette Publication Confirmation E-Mailed
Jan 25, 2022
Published For Opposition
Jan 5, 2022
Notification Of Notice Of Publication E-Mailed
Dec 21, 2021
Approved For Pub - Principal Register
Dec 21, 2021
Teas/Email Correspondence Entered
Dec 20, 2021
Correspondence Received In Law Office
Dec 20, 2021
Teas Response To Office Action Received
Oct 28, 2021
Notification Of Non-Final Action E-Mailed
Oct 28, 2021
Non-Final Action E-Mailed
Oct 28, 2021
Non-Final Action Written
Sep 15, 2021
Assigned To Examiner
May 22, 2021
New Application Office Supplied Data Entered In Tram
Feb 25, 2021
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
